Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 18
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 18

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderAkebia Therapeutics · 44
Strongest available pathCogent Biosciences · +316.2%
Widest latest marginAkebia Therapeutics · -2.3%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1AKBA · Nasdaq

Akebia Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2007Cincinnati, Ohio$254.6M market cap
View full Companies Radar profile
44Cautious
Snapshot price$0.92as of page date
Monthly-close return-68.1%five-year window
FY2025 revenue$0.24BAkebia Therapeutics, Inc.
Net margin-2.3%FY2025
P/E snapshot-2.8xone ratio, not a verdict
Prism attention39.8%share across these five
Filing track recordRevenue, USD billions
+10.6%
$0$0.1B$0.2B$0.3BFY2021: $0.214BFY2022: $0.293BFY2023: $0.195BFY2024: $0.160BFY2025: $0.236B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.5%
52-week position5% through range
$0.81$3.22
News mentions1.2K
Community mentions18partial coverage
U.S.-scope patents539
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal45/100
Management stability90/100
Market position9/100
Capital-event signal44/100
Innovation pulse27/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 9 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2COGT · Nasdaq

Cogent Biosciences

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2014Cambridge, Massachusetts$6.07B market cap
View full Companies Radar profile
44Cautious
Snapshot price$35.00as of page date
Monthly-close return+316.2%five-year window
FY2021 revenue$0.01BCogent Biosciences, Inc.
Net margin-918.2%FY2021
P/E snapshot-31.6xone ratio, not a verdict
Prism attention18.4%share across these five
Filing track recordRevenue, USD billions
-19.1%
$0$0.0B$0.0B$0.0BFY2018: $0.010BFY2019: $0.022BFY2020: $0.008BFY2021: $0.008B2018201920202021
FY2018–FY2021 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -6.8%
52-week position73% through range
$11.60$43.73
News mentions535
Community mentions5partial coverage
U.S.-scope patents40
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal42/100
Management stability90/100
Market position0/100
Capital-event signal85/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3ISCO · OTC

International Stem Cell Corp.

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2001Carlsbad, California$3.0M market cap
View full Companies Radar profile
44Cautious
Snapshot price$0.37as of page date
Monthly-close return-30.2%five-year window
FY2025 revenue$0.01BInternational Stem Cell CORP
Net margin-4.6%FY2025
Prism attention10.9%share across these five
Filing track recordRevenue, USD billions
+26.8%
$0$0.0B$0.0B$0.0BFY2021: $0.007BFY2022: $0.008BFY2023: $0.008BFY2024: $0.009BFY2025: $0.009B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 6.1%
52-week position60% through range
$0.12$0.54
News mentions317
Community mentions0partial coverage
U.S.-scope patents0
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal60/100
Management stability90/100
Market position6/100
Capital-event signal49/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4RMTI · Nasdaq

Rockwell Medical

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1995Troy$33.5M market cap
View full Companies Radar profile
44Cautious
Snapshot price$8.31as of page date
Monthly-close return-87.4%five-year window
FY2025 revenue$0.07BROCKWELL MEDICAL, INC.
Net margin-7.7%FY2025
Prism attention25.4%share across these five
Filing track recordRevenue, USD billions
+11.8%
$0$0.0B$0.1B$0.1BFY2021: $0.062BFY2022: $0.073BFY2023: $0.084BFY2024: $0.101BFY2025: $0.069B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.8%
52-week position24% through range
$4.89$19.10
News mentions736
Community mentions0partial coverage
U.S.-scope patents46
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal36/100
Management stability90/100
Market position18/100
Capital-event signal75/100
Innovation pulse3/100
Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 1 asset-acquisition events and 30 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5VREOF · OTCQX

Vireo Growth

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2014Minneapolis, Minnesota$542.7M market cap
View full Companies Radar profile
44Cautious
Snapshot price$10.52as of page date
Monthly-close return-78.1%five-year window
FY2025 revenue$0.27BVireo Growth Inc.
Net margin-25.3%FY2025
P/E snapshot5.4xone ratio, not a verdict
Prism attention5.5%share across these five
Filing track recordRevenue, USD billions
+393.6%
$0$0.1B$0.2B$0.3BFY2021: $0.054BFY2022: $0.075BFY2023: $0.088BFY2024: $0.099BFY2025: $0.269B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 49.1%
52-week position12% through range
$8.91$22.50
News mentions160
Community mentions0partial coverage
U.S.-scope patents0
Prism Insights

What sits behind the readiness signal

Observed risk 2/100higher means more observed risk
Earnings signal75/100
Management stability70/100
Market position26/100
Capital-event signal25/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 30 M&A involvements, 9 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Cogent Biosciences
+316.2%
International Stem Cell Corp.
-30.2%
Akebia Therapeutics
-68.1%
Vireo Growth
-78.1%
Rockwell Medical
-87.4%

Latest revenue

USD billions, official filing scope shown on each company card.

Vireo Growth
$0.27B
Akebia Therapeutics
$0.24B
Rockwell Medical
$0.07B
International Stem Cell Corp.
$0.01B
Cogent Biosciences
$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Akebia Therapeutics
-2.3%
International Stem Cell Corp.
-4.6%
Rockwell Medical
-7.7%
Vireo Growth
-25.3%
Cogent Biosciences
-918.2%

Prism news attention

Normalized share across these five names; attention is not quality.

Akebia Therapeutics
39.8%
Rockwell Medical
25.4%
Cogent Biosciences
18.4%
International Stem Cell Corp.
10.9%
Vireo Growth
5.5%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Akebia Therapeutics leads the conversation

It holds 39.8% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.24B.

Price path

Cogent Biosciences leads the available price paths

Its monthly-close return is +316.2% for the five-year window. At the other end, Rockwell Medical is -87.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Akebia Therapeutics has the widest latest margin

Its FY2025 net margin is -2.3%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Cogent Biosciences shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -31.6x while its five-year window price return is +316.2%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · AKBA

Akebia Therapeutics

1,152available Prism news records

Prism top themes

Price action & investor response
51
Capital allocation & transactions
39
Earnings & financial performance
29
Leadership & governance
28
Legal, arbitration & regulatory
16

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+27.7%166 latest 12m vs 130 prior 12m
2024-01: 17 mentions2024-02: 5 mentions2024-03: 27 mentions2024-04: 3 mentions2024-05: 13 mentions2024-06: 13 mentions2024-07: 16 mentions2024-08: 6 mentions2024-09: 2 mentions2024-10: 10 mentions2024-11: 10 mentions2024-12: 1 mentions2025-01: 11 mentions2025-02: 22 mentions2025-03: 20 mentions2025-04: 13 mentions2025-05: 8 mentions2025-06: 11 mentions2025-07: 7 mentions2025-08: 8 mentions2025-09: 7 mentions2025-10: 18 mentions2025-11: 12 mentions2025-12: 11 mentions2026-01: 17 mentions2026-02: 21 mentions2026-03: 4 mentions2026-04: 43 mentions2026-05: 16 mentions2026-06: 2 mentions2024-012026-06

Machine-classified coverage tone

93.5% positive-4.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 19company valuation 16startup valuation 13investor conference 7share price 4stock performance 4market reaction 4angiogenesis inhibitors 3

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-05–2026-06-07 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

AKBA

Akebia Therapeutics

through 2026-04-03
Earnings releases 17Company announcements 9Leadership changes 5Regulatory 3Business contracts 1
  1. Company announcements

    "He described Vafseo as positioned for significant growth in what he called a "billion-dollar market in 2026"."

  2. Earnings releases

    Revenues: Total revenues increased to $62.5 million in the second quarter of 2025 compared to $43.6 million in the second quarter of 2024, driven by sales of Vafseo, which was launched in the U.S. in January 2025, and an increase in Auryxia sales.

  3. Listing / IPO

    Akebia Therapeutics Inc. priced 7.25 million shares at $9 each for gross proceeds of $65.3 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

COGT

Cogent Biosciences

through 2026-01-13
Earnings releases 12Company announcements 5Listing / IPO 2Regulatory 1
  1. Earnings releases

    Based on Cogent Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $80.93 million.

  2. Company announcements

    Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 9,677,420 shares of its common stock at a public offering price of $31.00 per share (such offering, the “Equity Offering”) and its underwritten public offering of $200.0 million aggregate principal amount of its 1.625% convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”).

  3. Listing / IPO

    Cogent has commenced underwritten public offerings of $200 million aggregate principal amount of its convertible senior notes due 2031...

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ISCO

International Stem Cell Corp.

through 2025-02-14
Company announcements 3Earnings releases 3Leadership changes 2Listing / IPO 1M&A 1
  1. Leadership changes

    International Stem Cell Corp., of Oceanside, Calif., named Hans-Dieter Volk and Matthias von Herrath to its scientific advisory board.

  2. M&A

    As a result, ISC became a wholly-owned subsidiary of BTHC.

  3. Earnings releases

    International Stem Cell (OTC BB: ISCO) net loss of $2.47M or $0.03 per share with $4.29M in cash;

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RMTI

Rockwell Medical

through 2026-01-20
Earnings releases 24Business contracts 19Leadership changes 9M&A 4Company announcements 3
  1. Earnings releases

    The Company expects net sales for the fourth quarter 2025 to be approximately $18.6 million.

  2. Company announcements

    Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI) ... today announced that the Company has added 30 new customers in the western portion of the United States.

  3. Business contracts

    the Amended and Restated Product Purchase Agreement (the 'Amended Agreement') dated September 18, 2023 between the Company and one of the largest dialysis providers in the United States (the 'Customer') has been extended through December 31, 2026.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VREOF

Vireo Growth

through 2026-04-30
M&A 24Asset acquisitions 9Earnings releases 6Business contracts 2Lawsuits 1
  1. M&A

    Multistate operator Vireo Growth Inc. signed a definitive agreement to acquire multistate operator FLUENT Corp. in an all-stock transaction.

  2. Asset acquisitions

    Vireo Growth is planning to buy The Hawthorne Gardening Company, which sells products like plant nutrients, grow lights, and gardening supplies for indoor and hydroponic (soil-free) gardening across North America.

  3. Earnings releases

    Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 86–93. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Rockwell Medical has the widest attention-readiness rank gap

It ranks #2 by measured news attention (25.4%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Rockwell Medical in Companies Radar

Vireo Growth shows a price-operating divergence to inspect

Its displayed filing-revenue change is +393.6% while its available monthly-close return is -78.1%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Vireo Growth in Companies Radar
Explanations

Attention measures coverage volume, not quality

Akebia Therapeutics's 39.8% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Akebia Therapeutics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Akebia Therapeutics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 44/100 score.

Open Akebia Therapeutics in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon